Yüklüyor......
Selexipag in the management of pulmonary arterial hypertension: an update
Selexipag is a compound that was designed to overcome the issues associated with oral administration of prostanoid compounds, beraprost and treprostinil in the treatment of pulmonary hypertension (PAH). As a selective IP agonist, it was designed to avoid the off-target prostanoid effects especially...
Kaydedildi:
| Yayımlandı: | Drug Healthc Patient Saf |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6689562/ https://ncbi.nlm.nih.gov/pubmed/31496830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S181313 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|